Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) announced strong financial results for the second quarter of 2025. The company reported a 28% year-on-year increase in Q2 revenue to ₹2,209 million, supported by export operations and successful product launches. Thereby, sales growth stood at 27.5% from Q1 2025 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached ₹607 million, a 21% increase over Q1 2025.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”
During the half year, the company launched Allegra D, a unique proposition in the Allergy segment, also relaunched Depura 60k and Combiflam Suspension which were recalled voluntarily last year. Other legacy brands such as Avil, and Depura continue to uphold strong consumer trust and drive long-term relevance in their respective categories.
Financial highlights
Sale of Products
Q2 2025: ₹2,209 million
H1 2025: ₹3,935 million
Profit After Tax
Q2 2025: ₹606 million
H1 2025: ₹1,107 million